...
首页> 外文期刊>Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research >Evaluation of the bioactive extract of actinomyces isolated from the Egyptian environment against aflatoxin B1-induce cytotoxicity, genotoxicity and oxidative stress in the liver of rats
【24h】

Evaluation of the bioactive extract of actinomyces isolated from the Egyptian environment against aflatoxin B1-induce cytotoxicity, genotoxicity and oxidative stress in the liver of rats

机译:从埃及环境中分离出埃及环境的辐射素生物活性提取物的评价对大鼠肝脏肝脏诱导细胞毒性,遗传毒性和氧化应激

获取原文
获取原文并翻译 | 示例
           

摘要

This study aimed to determine the bioactive compounds of actinomyces (ACT) isolated from the Egyptian environment (D-EGY) and to evaluate their protective activity against AFB(1) in female Sprague-Dawley rats. Six groups of animals were treated orally for 3 weeks included: C, the control group, Tl, AFB(1)-treated group (80 mu g/kg b.w), T2 and T3, the groups received ACT extract at low (25 mg/kg b.w) or high (50 mg/kg b.w) doses, T4 and T5, the groups received AFB(1) plus the low or high dose of ACT extract. Blood, bone marrow and tissue samples were collected for different analyses and histological examination. The results revealed the identification of 40 components, representing 99.98%. Treatment with AFB(1) disturbs liver function parameters, oxidative stress markers, antioxidant gene expressions, DNA fragmentation and induced severe histological changes. ACT extract at the low or high doses did not induce significant changes in all the tested parameters or histological picture of the liver. Moreover, ACT extract succeeded to induce a significant protection against the toxicity of AFB(1). It could be concluded that the bioactive compounds in ACT are promise candidate for the development of food additive or drugs for the protection and treatment of liver disorders in the endemic area. (C) 2017 Elsevier Ltd. All rights reserved.
机译:本研究旨在确定从埃及环境(D-E-EGY)中分离的放射素(ACT)的生物活性化合物,并评估其对雌性Sprague-Dawley大鼠的AFB(1)的保护活性。将六组动物进行治疗3周,包括:C,对照组,T1,AFB(1) - 处理基团(80μmg/ kg bw),T2和T3,该基团在低(25mg / kg bw)或高(50mg / kg bw)剂量,t4和t5,基团接受AFB(1)加上的低剂量的ACT提取物。收集血液,骨髓和组织样品进行不同的分析和组织学检查。结果表明,鉴定了40个组分,代表99.98%。用AFB(1)治疗(1)扰动肝功能参数,氧化应激标记,抗氧化基因表达,DNA碎片和诱导严重的组织学变化。低剂量的动作提取物在肝脏的所有测试参数或组织学影中没有诱导显着的变化。此外,Act提取物成功地诱导了对AFB(1)的毒性的显着保护。可以得出结论,行动中的生物活性化合物是候选食品添加剂或用于保护和治疗地方性区域肝病的药物的承诺候选者。 (c)2017 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号